Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 54,948 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07846683
View directory record Official record
Conditions
Moderately to Severely Active Ulcerative Colitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cordova, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Not listed Phase 4 Interventional

Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

NCT05307341
View directory record Official record
Conditions
Pain
Interventions
sufentanil
Drug
Lead sponsor
More Foundation
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Nov 9, 2026, 12:42 AM EST
Completed Not applicable Interventional

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

NCT00590941
View directory record Official record
Conditions
Lymphoma, Diffuse Large Cell
Interventions
Blood draw
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Nov 9, 2026, 12:42 AM EST
Completed No phase listed Observational

Acute Pain Caused by Paclitaxel in Patients With Cancer

NCT00860041
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pain questionnaires
Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
279
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Nov 9, 2026, 12:42 AM EST
Active, not recruiting Phase 2 Interventional

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

NCT05065554
View directory record Official record
Conditions
IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral
Interventions
Acalabrutinib, Rituximab
Drug
Lead sponsor
Shayna Sarosiek, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 3 Interventional Results available

Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

NCT02898454
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Interventions
Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Nov 9, 2026, 12:42 AM EST
Not listed Phase 4 Interventional

A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome

NCT04515966
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Methylprednisolone Injection [Solu-Medrol], wrist splint
Drug · Device
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Nov 9, 2026, 12:42 AM EST
Recruiting Not applicable Interventional

ASV Therapy for Insomnia

NCT07011966
View directory record Official record
Conditions
Insomnia, Insomnia (Moderate)
Interventions
ASV therapy
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 1Phase 2 Interventional Results available

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

NCT01111825
View directory record Official record
Conditions
Breast Cancer
Interventions
Temsirolimus, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
Goodyear, Arizona • Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Nov 9, 2026, 12:42 AM EST
Active, not recruiting Not applicable Interventional

Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer

NCT02722525
View directory record Official record
Conditions
Cardiovascular Injury, Prostate Carcinoma
Interventions
Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging, Spectroscopy, Laboratory Biomarker Analysis
Procedure · Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 1 Interventional

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03544125
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Durvalumab, Olaparib
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Nov 9, 2026, 12:42 AM EST
Not yet recruiting Not applicable Interventional

Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors

NCT07250425
View directory record Official record
Conditions
Stroke, Neurological Diseases or Conditions, Hemiparesis;Poststroke/CVA, Gait Disorders, Neurologic, Post Stroke Fatigue, Motor Recovery, Walking Difficulty, Balance Impairment, Falls Prevention, Hemiparesis, Mobility Limitation
Interventions
Rise&Walk InHome by Healing Innovations
Device
Lead sponsor
Healing Innovations
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Terminated No phase listed Observational

Sample Collection From Melanoma Patients

NCT00507325
View directory record Official record
Conditions
Melanoma
Interventions
Blood Sample, Tumor Sample
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 4 Interventional Results available

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

NCT01448525
View directory record Official record
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 3 Interventional Results available

A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia

NCT03893825
View directory record Official record
Conditions
Schizophrenia
Interventions
TV-46000, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
67
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 2 Interventional

Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

NCT00004017
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
Procedure · Radiation
Lead sponsor
Peregrine Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Charlotte, North Carolina • Philadelphia, Pennsylvania • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Nov 9, 2026, 12:42 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

NCT03322189
View directory record Official record
Conditions
Pharmacogenomic
Interventions
pharmacogenomic
Genetic
Lead sponsor
Data Collection Analysis Business Management
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Nov 9, 2026, 12:42 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Show Rates in Dental Care Settings Serving Underserved Populations

NCT06581250
View directory record Official record
Conditions
Dental Care
Interventions
Reminder Messages, Walk-in Visits, Motivation-enhanced Communication
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 1 Interventional

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

NCT00000391
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide T
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1988
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Nov 9, 2026, 12:42 AM EST
Completed Not applicable Interventional Results available

Reducing Asymmetry During Gait Using the TPAD (Tethered Pelvic Assist Device) for Stroke Patients

NCT03203291
View directory record Official record
Conditions
Stroke
Interventions
TPAD (Tethered Pelvic Assist Device)
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

NCT02833350
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853, Adalimumab, Folic Acid, MTX, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Nov 9, 2026, 12:42 AM EST
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 9, 2026, 12:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite

NCT02859597
View directory record Official record
Conditions
Morbid Obesity, Noninvasive Ventilation, Deep Sedation
Interventions
High flow nasal cannula, Nasal Cannula
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Nov 9, 2026, 12:42 AM EST